Using gene expression profiling to identify a prognostic molecular spectrum in gliomas

Cancer Science

Volumn 100, Issue 1, 2009, Pages 165-172

  Shirahata, Mitsuaki ^a,b   Oba, Shigeyuki ^c   Iwao Koizumi, Kyoko ^b   Saito, Sakae ^b   Ueno, Noriko ^b   Oda, Masashi ^a   Hashimoto, Nobuo ^a   Ishii, Shin ^c   Takahashi, June A ^a   Kato, Kikuya ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NIMUSTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CLASSIFICATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXPRESSED SEQUENCE TAG; FOLLOW UP; GENE EXPRESSION PROFILING; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONOTHERAPY; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; PROGNOSIS;

EID: 58149301357     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01002.x     Document Type: Article

References (39)

1. Louis DN, Holland EC, Cairncross JG. Glioma classification: A molecular reappraisal. Am J Pathol 2001; 159: 779-86.
2. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-9.
3. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
4. Shirahata M, Iwao-Koizumi K, Saito S et al. A gene expression-based molecular diagnostic system for malignant gliomas displays clinical utility, prognostic ability and reproducibility superior to histological diagnosis. Clin Cancer Res 2007; 13: 7341-56.
5. Aoki T, Takahashi JA, Ueba T et al. Phase II study of nimustine, carboplatin, vincristine, and interferon-β with radiotherapy for glioblastoma multiforme: Experience of the Kyoto Neuro-Oncology Group. J Neurosurg 2006; 105: 385-91.
6. Kleihues P, Cavenee WK. World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System. Lyon: IARC Press, 2000.
7. Matoba R, Kato K, Saito S et al. Gene expression in mouse cerebellum during its development. Gene 2000; 241: 125-31.
8. Iwao-Koizumi K, Matoba R, Ueno N et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23: 422-31.
9. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6.
10. Japan CoBTRo. Report of Brain Tumor Registry of Japan (1969-96). Neurologia Medico-Chirurgica 2003; 43. Suppl: 1-111.
11. Oba S, Sato MA, Takemasa I, Monden M, Matsubara K, Ishii S. A Bayesian missing value estimation method for gene expression profile data. Bioinformatics (Oxford, England) 2003; 19: 2088-96.
12. Nutt CL, Mani DR, Betensky RA et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003; 63: 1602-7.
13. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-73.
14. Alter O, Brown PO, Botstein D. Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci USA 2000; 97: 10.101-6.
15. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. Plos Biol 2004; 2: E108.
16. Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol 2001; 19: 509-18.
17. Chang CH, Horton J, Schoenfeld D et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52: 997-1007.
18. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-97.
19. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-18.
20. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
21. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323-9.
22. Freije WA, Castro-Vargas FE, Fang Z et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004; 64: 6503-10.
23. Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-10.
24. Bussolati B, Ahmed A, Pemberton H et al. Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: Induction of angiogenesis and inhibition of leukocytic infiltration. Blood 2004; 103: 761-6.
25. Deryugina EI, Bourdon MA. Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 1996; 109 (Pt 3): 643-52.
26. Godard S, Getz G, Delorenzi M et al. Classification of human astrocytic gliomas on the basis of gene expression: A correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003; 63: 6613-25.
27. Gondi CS, Lakka SS, Yanamandra N et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003; 22: 5967-75.
28. Nishie A, Ono M, Shono T et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 1999; 5: 1107-13.
29. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-8.
30. Rorive S, Belot N, Decaestecker C et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 2001; 33: 241-55.
31. Song SW, Fuller GN, Khan A et al. IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc Natl Acad Sci USA 2003; 100: 13.970-5.
32. Tran NL, McDonough WS, Savitch BA et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via rac1 and nuclear factor-κB and correlate with poor patient outcome. Cancer Res 2006; 66: 9535-42.
33. Wang H, Wang H, Shen W et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 2003; 63: 4315-21.
34. Mukasa A, Ueki K, Ge X et al. Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol (Zurich, Switzerland) 2004; 14: 34-42.
35. Mukasa A, Ueki K, Matsumoto S et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002; 21: 3961-8.
36. Ein-Dor L, Kela I, Getz G, Givol D, Domany E. Outcome signature genes in breast cancer: Is there a unique set? Bioinformatics (Oxford, England) 2005; 21: 171-8.
37. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 2004; 54: 349-57.
38. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurgery 2001; 95: 190-8.
39. Athanassiou H, Synodinou M, Maragoudakis E et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23: 2372-7.